OncoSec Medical Receives a Buy from Noble Financial

By Jason Carr

Noble Financial analyst Mark Jordan reiterated a Buy rating on OncoSec Medical (NASDAQ: ONCS) on March 17. The company’s shares closed last Friday at $1.24, close to its 52-week low of $1.03.

According to TipRanks.com, Jordan is a 3-star analyst with an average return of 5.4% and a 62.0% success rate. Jordan covers the Technology sector, focusing on stocks such as Comtech Telecommunications, OmniComm Systems Inc, and Innodata Isogen Inc.

OncoSec Medical has an analyst consensus of Strong Buy.

Based on OncoSec Medical’s latest earnings report for the quarter ending October 31, the company posted quarterly revenue of $0 and GAAP net loss of $5.6 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $7.04 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

OncoSec Medical, Inc. engages in designing, developing and commercializing medical products for the treatment of cancer. It engages in the discovery and development of novel immunotherapeutic products to improve treatment options for patients and physicians, which intends to treat oncology indications. The company was founded by Avtar S. Dhillon and Punit S. Dhillon on February 8, 2008 and is headquartered in San Diego, CA.